Rovin, Brad HBrad HRovinBarratt, JonathanJonathanBarrattHeerspink, Hiddo J LHiddo J LHeerspinkAlpers, Charles ECharles EAlpersBieler, StewartStewartBielerChae, Dong-WanDong-WanChaeDiva, Ulysses AUlysses ADivaFloege, JürgenJürgenFloegeGesualdo, LoretoLoretoGesualdoInrig, Jula KJula KInrigKohan, Donald EDonald EKohanKomers, RadkoRadkoKomersKooienga, Laura AnnLaura AnnKooiengaLafayette, RichardRichardLafayetteMaes, BartBartMaesMałecki, RobertRobertMałeckiMercer, AlexAlexMercerNoronha, Irene LIrene LNoronhaOh, Se WonSe WonOhPeh, Chen AuChen AuPehPraga, ManuelManuelPragaPreciado, PriscilaPriscilaPreciadoRadhakrishnan, JaiJaiRadhakrishnanRheault, Michelle NMichelle NRheaultRote, William EWilliam ERoteTang, Sydney C WSydney C WTangTesar, VladimirVladimirTesarTrachtman, HowardHowardTrachtmanTrimarchi, HernánHernánTrimarchiTumlin, James AJames ATumlinWong, Muh GeotMuh GeotWongPerkovic, VladoVladoPerkovicSZU-YU PAN et al.2024-03-112024-03-112023-12-0201406736https://scholars.lib.ntu.edu.tw/handle/123456789/640765Sparsentan, a novel, non-immunosuppressive, single-molecule, dual endothelin angiotensin receptor antagonist, significantly reduced proteinuria versus irbesartan, an angiotensin II receptor blocker, at 36 weeks (primary endpoint) in patients with immunoglobulin A nephropathy in the phase 3 PROTECT trial's previously reported interim analysis. Here, we report kidney function and outcomes over 110 weeks from the double-blind final analysis.enEfficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trialjournal article10.1016/S0140-6736(23)02302-4379316342-s2.0-85178234589https://api.elsevier.com/content/abstract/scopus_id/85178234589